Crossmark

miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome

Crossref DOI link: https://doi.org/10.1038/s41416-021-01602-8

Published Online: 2021-10-30

Published Print: 2022-01-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Papadimitriou, Maria-Alexandra

Papanota, Aristea-Maria

Adamopoulos, Panagiotis G.

Pilala, Katerina-Marina

Liacos, Christine-Ivy

Malandrakis, Panagiotis

Mavrianou-Koutsoukou, Nefeli

Patseas, Dimitrios

Eleutherakis-Papaiakovou, Evangelos

Gavriatopoulou, Maria

Kastritis, Efstathios https://orcid.org/0000-0001-8191-5832
Avgeris, Margaritis https://orcid.org/0000-0002-2135-9886
Dimopoulos, Meletios-Athanasios https://orcid.org/0000-0001-8990-3254
Terpos, Evangelos https://orcid.org/0000-0001-5133-1422
Scorilas, Andreas https://orcid.org/0000-0003-2427-4949
License Information

Text and Data Mining valid from 2021-10-30

Version of Record valid from 2021-10-30
More Information

Article History

Received: 27 April 2021

Revised: 10 July 2021

Accepted: 12 October 2021

First Online: 30 October 2021

Competing interests

: The authors declare no competing interests.

: The study was approved by the Ethics Committee of “Alexandra” Hospital, Athens, Greece, and all patients who participated were informed and signed an informed consent according to 1975 Declaration of Helsinki ethical standards, as revised in 2008.

: Not applicable.

Document is current

Any future updates will be listed below